EHA 2022 Congress
This year’s program features cutting-edge evidence-based approaches to diagnosis and treatment and highly anticipated clinical and translational research data.
Advertisement
Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL.
In the study, 11 patients with relapsed/refractory diffuse LBCL were infused with anbal-cel.
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
A phase III trial of magrolimab plus azacitidine versus standard of care in TP53-mutated AML is currently ongoing.
Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery.
Epcoritamab is a subcutaneous CD3/CD20 bispecific antibody that induces anti-tumor activity across B-cell NHL subtypes.
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.